Shares of Glenmark Pharma Ltd fell 2% after touching a day’s high of Rs 1,907.90 on 4th November. This happened even though the company announced that its US-based arm will launch the 8.4% Sodium Bicarbonate Injection USP. This injection is used to treat metabolic acidosis — a condition caused by excess acid production in the body.

Glenmark said its US arm will launch the 8.4% Sodium Bicarbonate Injection USP in November 2025. The injection, available in a 50 mEq/50 mL single-dose vial, is bioequivalent and therapeutically equivalent to Abbott Laboratories’ reference drug.

According to IQVIA data for the 12 months ending August 2025, the market for this injection recorded annual sales of about $63.8 million. It is used to treat metabolic acidosis — a condition caused by excess acid in the body. This occurs due to issues like severe kidney disease, uncontrolled diabetes, shock, dehydration, or cardiac arrest.

Marc Kikuchi, President and Business Head, North America, said the launch expands Glenmark’s injectable portfolio. It reinforces its focus on providing quality, affordable treatments. Glenmark added that its injection will be marketed only for the indications approved on its label.

At 1:08 PM, shares of Glenmark Pharma were trading 1.72% lower at Rs 1,865.70 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!